24 March 2026 : Review article
Review of the Effects of Anesthetic Techniques and Medications on the Immune Response During the Perioperative Period
Paweł RadkowskiDOI: 10.12659/MSM.951077
Med Sci Monit 2026; 32:e951077
Table 4 Differential impact of general and regional anesthesia on immune mechanisms, cytokine profiles, and clinical outcomes [12,14–17,20,22,32,38,60–62].
| Mechanism/parameter | General anesthesia | Regional anesthesia |
|---|---|---|
| Stress response | Triggers a strong surgical stress response | Reduces surgical stress response |
| Neuroendocrine modulation | Activates the HPA axis and the sympathetic nervous system | Limits activation of the HPA axis and sympathetic nervous system |
| Hormonal response | Increases cortisol and catecholamine secretion | Decreases cortisol and catecholamine secretion |
| Cytokine profile | Decreases IL-6, TNF-α, IL-1β (pro-inflammatory); increases IL-10 (anti-inflammatory) | Lowers pro-inflammatory cytokines (eg, IL-6, TNF-α); reduces systemic inflammatory response |
| Inflammatory response | Promotes immunosuppression and a weakened inflammatory reaction | Induces milder immune suppression and a less pronounced inflammatory response |
| Lymphocyte modulation | Decreases T-lymphocyte activity and antibody production by B-lymphocytes; weaker response to pathogens, increased risk of infections | More gradual Th1/Th2 transition; less suppression of immune cells |
| Antigen-presenting cells | Decreases macrophage and dendritic cell activity, resulting in reduced T-cell activation | Local anesthetics may modulate macrophage and monocyte activity and surface molecule expression |
| Neutrophils and phagocytosis | Decreases migration and phagocytic activity of neutrophils; reduced ability to fight infection | Better preservation of innate immune cell function |
| NK cells | Decreases NK cell activity; potential facilitation of infection or tumor spread | Preserves NK cell cytotoxic function compared with general anesthesia |
| Intestinal barrier integrity | Increases intestinal permeability; risk of microbiota imbalance, bacterial translocation, and risk of hospital-acquired infections | No significant disruption of intestinal barrier function reported |
| Postoperative immunity | Broad suppression of postoperative immune function | Better preservation of immune competence, particularly in cancer and immunocompromised patients |
| Oncologic implications | May enhance tumor dissemination and angiogenesis through immune suppression | May reduce perioperative tumor cell spread, angiogenesis and immune suppression during the perioperative period |
| Clinical outcomes | Associated with a higher risk of infection and a possible increase in tumor recurrence | No conclusive evidence of reduced tumor recurrence; available studies remain limited and biased |
| Research limitations | Moderate-quality evidence indicating immunosuppression | Data is mostly retrospective, with small sample sizes, inconsistent outcomes, low quality, and a high risk of bias |
| Recommendation | Use cautiously in immunocompromised or oncologic settings | Further randomized controlled trials needed; anesthetic choice should be individualized |
| Source: own. HPA – hypothalamic-pituitary-adrenal; IL-6 – interleukin 6; NK – natural killer; TNF-α – tumor necrosis factor α; IL-1β – interleukin 1β; IL-10 – interleukin 10; Th1 – T helper 1 cells; Th2 – T helper 2 cells. | ||






